# Farxiga (dapagliflozin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dapagliflozin

> Farxiga (dapagliflozin), sponsored by ASTRAZENECA PLC (AZN), received a complete response letter from the FDA; the decision is dated January 17, 2012.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Farxiga (dapagliflozin) |
| Codes |  |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | [Renal Insufficiency, Chronic](https://sec-api.dev/indications/renal-insufficiency-chronic), [Type 2 Diabetes Mellitus](https://sec-api.dev/indications/type-2-diabetes-mellitus), [Chronic Kidney Disease With High Proteinuria](https://sec-api.dev/indications/chronic-kidney-disease-with-high-proteinuria) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### January 17, 2012: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA202293_20120117.pdf%22

### May 5, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202293 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20200505, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product FARXIGA (DAPAGLIFLOZIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202293%22

### April 30, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202293 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20210430, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product FARXIGA (DAPAGLIFLOZIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202293%22

### May 8, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202293 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20230508, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product FARXIGA (DAPAGLIFLOZIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202293%22

### June 12, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202293 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20240612, review_priority PRIORITY; sponsor_name ASTRAZENECA AB; product FARXIGA (DAPAGLIFLOZIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202293%22

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Kidney Disease With High Proteinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06942910 (A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-26 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06942910

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Chronic Kidney Disease With High Proteinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06942910 (A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-26 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06942910

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Kidney Disease With High Proteinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06087835 (Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-18 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06087835

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Kidney Disease With High Proteinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06087835 (Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-18 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT06087835

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Type 2 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07662044 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-14 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07662044

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Type 2 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07662109 (A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-05 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07662109

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Type 2 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07662109 (A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-05 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07662109

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Type 2 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07662044 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-14 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07662044

### July 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Renal Insufficiency, Chronic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07624305 (A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07624305

### Jul to Oct 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Renal Insufficiency, Chronic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07624305 (A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-01 (ESTIMATED); Lead Sponsor AstraZeneca." https://clinicaltrials.gov/study/NCT07624305

## Same indication

- [Elecoglipron](https://sec-api.dev/pdufa/elecoglipron) (AZN)
- [Ormd-0801 8 mg](https://sec-api.dev/pdufa/ormd-0801) (ORMP)
- [Renal autologous cell therapy (react/ rilparencel)](https://sec-api.dev/pdufa/renal-autologous-cell-therapy-react-rilparencel) (PROK)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)

Calendar months: [September 2026](https://sec-api.dev/fda-calendar/2026-09), [February 2027](https://sec-api.dev/fda-calendar/2027-02), [July 2028](https://sec-api.dev/fda-calendar/2028-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dapagliflozin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Farxiga (dapagliflozin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dapagliflozin

```bibtex
@misc{secapidev_pdufa_dapagliflozin_20261116,
  title        = {Farxiga (dapagliflozin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dapagliflozin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dapagliflozin_20261116","title":"Farxiga (dapagliflozin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dapagliflozin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
